Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO2/FiO2 in severe COVID-19 pneumonia

Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO2/FiO2 in severe COVID-19 pneumonia

BackgroundDespite patients with severe coronavirus disease (COVID-19) receiving standard triple therapy, including steroids, antiviral agents, and anticytokine therapy, health condition of certain patients continue to deteriorate. In Taiwan, the COVID-19 mortality has been high since the emergence o...

Full description

Bibliographic Details
Main Authors: Chih-Hao Chen, Kuan-Cheng Chang, Yen-Nien Lin, Mao-Wang Ho, Meng-Yu Cheng, Wen-Hsin Shih, Chia-Huei Chou, Po-Chang Lin, Chih-Yu Chi, Min-Chi Lu, Ni Tien, Mei-Yao Wu, Shih-Sheng Chang, Wu-Huei Hsu, Woei-Cheang Shyu, Der-Yang Cho, Long-Bin Jeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
arterial partial pressure of oxygen vs. fraction of inspired oxygen
COVID-19
human umbilical cord mesenchymal stem cells
monocyte distribution width
inflammatory cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1001979/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1001979/full

Similar Items